Journals / Turkish Neurosurgery / 2019 / Cilt: 29 - Sayı: 1

Investigating the Levels of Soluble Extracellular Domain of HER2 Protein in the Sera of Meningioma Patients

Pages
9–13
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Furthermore, in meningiomas with higher histological grade (gradeII, III), statistically significant elevated serum levels of HER2 were observed compared to patients with low-grade meningiomas(grade I).CONCLUSION: Serum HER2 levels were a poor biomarker for determination of pathological and prognostic characteristics ofmeningiomas and coupling serum HER2 levels with immunohistochemistry examination of HER2 in meningioma tissue sampleswould be helpful in future studies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: Bearing in mind the association of breast cancer and meningioma, the present study aimed to investigate the levels ofthe soluble extracellular domain of HER2 protein in meningioma cases and control group.
📊
Key Findings & Data:Besides, in the present research, itsassociations with pathological features and prognostic indicators of meningioma were examined.MATERIAL and METHODS: A total of 68 meningioma patients along with 20 healthy age-sex matched individuals, as controls,were selected.
💡
Conclusion & Impact:Furthermore, in meningiomas with higher histological grade (gradeII, III), statistically significant elevated serum levels of HER2 were observed compared to patients with low-grade meningiomas(grade I).CONCLUSION: Serum HER2 levels were a poor biomarker for determination of pathological and prognostic characteristics ofmeningiomas and coupling serum HER2 levels with immunohistochemistry examination of HER2 in meningioma tissue sampleswould be helpful in future studies.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

AIM: Bearing in mind the association of breast cancer and meningioma, the present study aimed to investigate the levels ofthe soluble extracellular domain of HER2 protein in meningioma cases and control group. Besides, in the present research, itsassociations with pathological features and prognostic indicators of meningioma were examined.MATERIAL and METHODS: A total of 68 meningioma patients along with 20 healthy age-sex matched individuals, as controls,were selected. Levels of HER2 in the sera were measured by a quantitative enzyme-linked immunosorbent assay (ELISA).RESULTS: The observations showed that Serum HER2 levels in meningioma patients were significantly lower than normal controls.However, outlier quantities were mostly observed in the cases. Furthermore, in meningiomas with higher histological grade (gradeII, III), statistically significant elevated serum levels of HER2 were observed compared to patients with low-grade meningiomas(grade I).CONCLUSION: Serum HER2 levels were a poor biomarker for determination of pathological and prognostic characteristics ofmeningiomas and coupling serum HER2 levels with immunohistochemistry examination of HER2 in meningioma tissue sampleswould be helpful in future studies.

🔖

Cite This Article

ABTAHI, S., HAKIMRABET, S., MALEKZADEH, M., DEGHANIAN, A. R., GHADERI, A. (2019). Investigating the Levels of Soluble Extracellular Domain of HER2 Protein in the Sera of Meningioma Patients. Turkish Neurosurgery, Cilt: 29 - Sayı: 1, 9–13. https://ajindex.com/articles/404444

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. [No authors listed]: "ERBB2 Erb-b2 Receptor Tyrosine Kinase 2 [Homo Sapiens (human)] - Gene - NCBI." National Center for Biotechnology Information. U.S. National Library of Medicine, n.d. Web. 18 July 2017. 2. Abdelzaher E, El-Gendi SM, Yehya A, Gowil AG: Recurrence of benign meningiomas: Predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression. Br J Neurosurg 25: 707-713, 2011 3. Andersson U, Guo D, Malmer B, Bergenheim AT, Brannstrom T, Hedman H, Henriksson R: Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. Acta Neuropathol 108: 135-142, 2004 4. Blume-Jensen P, Hunter T: Oncogenic kinase signalling. Nature 411:355-365, 2001 5. Chozick BS, Benzil DL, Stopa EG, Pezzullo JC, Knuckey NW, Epstein MH, Finkelstein SD, Finch PW: Immunohistochemical evaluation of erbB-2 and p53 protein expression in benign and atypical human meningiomas. J Neurooncol 27: 117-126, 1996 6. Custer BS, Koepsell TD, Mueller BA: The association between breast carcinoma and meningioma in women. Cancer 94: 1626-1635, 2002 7. Durand A, Champier J, Jouvet A, Labrousse F, Honnorat J, Guyotat J, Fevre-Montange M: Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: Relation to grades or histotypes. Clin Neuropathol 27: 334-345, 2008 8. Finn OJ: Cancer immunology. N Engl J Med 358: 2704-2715, 2008 9. Krishnamurti U, Silverman JF: HER2 in breast cancer: A review and update. Adv Anat Pathol 21: 100-107, 2014 10. Laurendeau I, Ferrer M, Garrido D, D'Haene N, Ciavarelli P, Basso A, Vidaud M, Bieche I, Salmon I, Szijan I: Gene expression profiling of ErbB receptors and ligands in human meningiomas. Cancer Invest 27: 691-698, 2009 11. Lauterlein JJ, Petersen ER, Olsen DA, Ostergaard B, Brandslund I: Quantification of HER2 autoantibodies in the amplification phenomenon of HER2 in breast cancer. Clin Chem Lab Med 49:877-883, 2011 12. Louis DN, Perry A, Reifenberger G, von Deimling A, FigarellaBranger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW: The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. Acta Neuropathol 131: 803-820, 2016 13. Loussouarn D, Brunon J, Avet-Loiseau H, Campone M, Mosnier JF: Prognostic value of HER2 expression in meningiomas: An immunohistochemical and fluorescence in situ hybridization study. Hum Pathol 37: 415-421, 2006 14. Mahzouni P, Movahedipour M: An immunohistochemical study of HER2